Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression.
about
The connection domain in reverse transcriptase facilitates the in vivo annealing of tRNALys3 to HIV-1 genomic RNAThe Host RNAs in Retroviral ParticlesBiodistribution of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar, without Integration, despite Differing Plasmid Backbones or Gene InsertsMechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation InhibitorsExpression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccinesElicitation of anti-1918 influenza virus immunity early in life prevents morbidity and lower levels of lung infection by 2009 pandemic H1N1 influenza virus in aged mice.Inability of human immunodeficiency virus type 1 produced in murine cells to selectively incorporate primer formula.Dynamic fluorescent imaging of human immunodeficiency virus type 1 gag in live cells by biarsenical labeling.Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primatesEnhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens.A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primatesFilamin A protein interacts with human immunodeficiency virus type 1 Gag protein and contributes to productive particle assembly.7SL RNA is retained in HIV-1 minimal virus-like particles as an S-domain fragment.Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization.Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene.Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 GStable expression of primary human immunodeficiency virus type 1 structural gene products by use of a noncytopathic sindbis virus vectorIndependent segregation of human immunodeficiency virus type 1 Gag protein complexes and lipid rafts.The role of A-kinase anchoring protein 95-like protein in annealing of tRNALys3 to HIV-1 RNA.The cellular source for APOBEC3G's incorporation into HIV-1.Coordinate roles of Gag and RNA helicase A in promoting the annealing of formula to HIV-1 RNAStrategies for designing and optimizing new generation vaccines.New hope for an AIDS vaccine.The roles of APOBEC3G complexes in the incorporation of APOBEC3G into HIV-1.Next generation DNA vaccines for HIV-1.Different patterns of expansion, contraction and memory differentiation of HIV-1 Gag-specific CD8 T cells elicited by adenovirus type 5 and modified vaccinia Ankara vaccines.Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.Cellular distribution of Lysyl-tRNA synthetase and its interaction with Gag during human immunodeficiency virus type 1 assembly.Identification of molecular determinants from Moloney leukemia virus 10 homolog (MOV10) protein for virion packaging and anti-HIV-1 activity.DNA vaccines against human immunodeficiency virus type 1 in the past decade.Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag.PSF acts through the human immunodeficiency virus type 1 mRNA instability elements to regulate virus expressionIdentification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage.Siglec-1 initiates formation of the virus-containing compartment and enhances macrophage-to-T cell transmission of HIV-1.Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens.Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization.Insulin-like growth factor II mRNA binding protein 1 associates with Gag protein of human immunodeficiency virus type 1, and its overexpression affects virus assembly.Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vectorIncorporation of pol into human immunodeficiency virus type 1 Gag virus-like particles occurs independently of the upstream Gag domain in Gag-pol
P2860
Q24806162-B7911739-B18F-47F8-AB69-C8C6EBB98148Q26739938-1127D1CC-08E8-4836-B365-060FA7967E30Q27486035-46C92B49-8EEA-4347-BBCC-6CE924AB8DC7Q28554482-9BD4DC59-BCC2-411D-8D00-45063D13B02BQ30332833-6568D94E-A08F-4F3B-8E2F-DE75D8FA5E60Q30410129-3B3B50E3-17B1-4FAD-9883-1C25A1CE7BDBQ30439541-C85BB405-B1E4-4011-92A4-35E3C0249DCFQ33707507-6B629D63-0F8C-4802-9FE4-9950E4407578Q33780685-161D0328-12B8-4D9F-BAB1-291C0D0C45EDQ33843258-865286A8-336A-4D91-952B-F45D56409781Q33883854-4ECABA0F-5B70-480C-8DB6-D08946E99E64Q33943140-C7A82B12-882D-4D30-98D6-9B57572677BEQ34120220-354E0EE8-D676-4851-8049-FFA1BC61BFC9Q34142795-D93D49B2-1A10-4E4E-A1DF-3DF711D12CC2Q34326532-FA55969C-80F6-49FD-8535-5B84C143950CQ34342982-0997BDDE-E916-4EA3-BDC5-A662A8AF80FEQ34356433-E34B4E06-F757-4810-AFFA-965D1A30BCA7Q34466295-C45540FA-52BB-4A69-8B5D-362F412ED702Q34468488-FDBBC8B7-E420-4B41-AD2F-D1904061A0ACQ34506802-ABADA7AE-145A-4AFB-B984-3055EEB97036Q34529769-45E41051-9E8C-40A7-B242-64B95E35B115Q34572198-B168E9B3-94CD-469D-A72E-9FD821E80CF3Q34632063-062DF331-3062-4CA1-8FAC-5FE6DB5412BBQ35009019-FA46F123-9167-415F-A0DD-E172D9B194BFQ35072785-CB7F1B64-ECD7-4BDB-90BC-9303A9546211Q35113347-BBD5EA11-9C90-4E08-BA2F-92A93A8D99D2Q35123128-E3D73C43-BFFE-46F6-B066-B2A4E7F69CDCQ35123403-45E9B50C-6DA0-4C36-ACC8-61A007F54071Q35668775-33730C17-06F6-43E9-8829-2FC938782440Q35745831-E7AB7762-A98D-4ECD-B907-B8ADDDF8B34FQ35750430-AA149F52-B688-46C5-9400-C66486BEA470Q35920650-8FE13577-0762-4465-8BEB-EFF539CD560BQ35992805-8A58A2EC-9368-472C-B857-D80229FE53EDQ36262599-C9345000-D232-4B24-825E-A2227105E468Q36638450-8380E2D0-1222-4D19-AAAA-E5E1019A1AEEQ36663607-F085FF9C-81FF-4054-87DB-F97A51072495Q36673246-0D1E3373-6AC7-4636-9345-E29D1794C927Q36720978-E0421717-C90B-48A2-BEFB-8A62E0678582Q36720991-069D9E15-652B-4B10-85F4-CDFABAFE15CCQ36942505-B10F896D-17DB-4505-9312-C22410CCC6B8
P2860
Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Human immunodeficiency virus t ...... ion of Gag and Pol expression.
@ast
Human immunodeficiency virus t ...... ion of Gag and Pol expression.
@en
type
label
Human immunodeficiency virus t ...... ion of Gag and Pol expression.
@ast
Human immunodeficiency virus t ...... ion of Gag and Pol expression.
@en
prefLabel
Human immunodeficiency virus t ...... ion of Gag and Pol expression.
@ast
Human immunodeficiency virus t ...... ion of Gag and Pol expression.
@en
P2093
P2860
P1433
P1476
Human immunodeficiency virus t ...... ion of Gag and Pol expression.
@en
P2093
P2860
P304
P356
10.1128/JVI.75.10.4947-4951.2001
P577
2001-05-01T00:00:00Z